For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $9.43 in the prior trading day, Bicara Therapeutics Inc (NASDAQ: BCAX) closed at $828.01K, up 583780%. In other words, the price has increased by $583780 from its previous closing price. On the day, 0.58 million shares were traded. BCAX stock price reached its highest trading level at $9.7779 during the session, while it also had its lowest trading level at $9.08.
Ratios:
Our goal is to gain a better understanding of BCAX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.62 and its Current Ratio is at 24.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.
On February 06, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $31.Wedbush initiated its Outperform rating on February 06, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Meisner Lara sold 15,829 shares for $10.43 per share. The transaction valued at 165,096 led to the insider holds 0 shares of the business.
LARA S. MEISNER bought 31,658 shares of BCAX for $343,173 on Jun 16 ’25. On Mar 14 ’25, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 79,146 shares for $12.90 each. As a result, the insider received 1,021,211 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 508277376 and an Enterprise Value of 46803552.
Stock Price History:
Over the past 52 weeks, BCAX has reached a high of $28.09, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is -24.51%, while the 200-Day Moving Average is calculated to be -42.63%.
Shares Statistics:
The stock has traded on average 828.01K shares per day over the past 3-months and 635970 shares per day over the last 10 days, according to various share statistics. A total of 54.53M shares are outstanding, with a floating share count of 32.77M. Insiders hold about 39.92% of the company’s shares, while institutions hold 62.30% stake in the company. Shares short for BCAX as of 1748563200 were 6578158 with a Short Ratio of 7.94, compared to 1745971200 on 6495930. Therefore, it implies a Short% of Shares Outstanding of 6578158 and a Short% of Float of 18.879999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Bicara Therapeutics Inc (BCAX) reflects the collective analysis of 6 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.55, with high estimates of -$0.38 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.79 and -$2.75 for the fiscal current year, implying an average EPS of -$2.28. EPS for the following year is -$2.43, with 6.0 analysts recommending between -$1.67 and -$2.97.
